louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03518411: Adaptation of the One-session CBT Protocol for Prevention of Mental Illness for Brazilian Portuguese
Official title: Adaptation of the One-session CBT Protocol for Prevention of Mental Illness for Brazilian Portuguese: Open Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Mental Disorder
CBT
Lead sponsor: Hospital de Clinicas de Porto Alegre
Sponsor class: OTHER
First posted: 2018-05-08
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: 1. Recruitment of medicine students of federal university.
2. Psychiatric interview (MINI) and sclaes application.
3. Protocol of CBT
4. Scales and MINI will be applied at the times of 7, 30 and 90 days after the end of the therapy.
5. Statistical analysis


Eligibility criteria: Inclusion Criteria:

* be medical student
* be over 18 years of age
* agree to the Term of Free and Informed Consent.

Exclusion Criteria:

* Students with psychotic illness, severe depression, manic episode or acute psychiatric risk.

Primary outcomes:
measure: Prevention of anxiety symptoms
timeFrame: 90 days after
Secondary outcomes:
measure: Prevention of depression symptoms
timeFrame: 90 days after
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Hospital de Clínicas de Porto Alegre
state: Rio Grande Do Sul
Study officials:
affiliation: Hospital de Clínicas de Porto Alegre
name: Carolina Blaya
role: STUDY_DIRECTOR
References:
citation: Fisak BJ Jr, Richard D, Mann A. The prevention of child and adolescent anxiety: a meta-analytic review. Prev Sci. 2011 Sep;12(3):255-68. doi: 10.1007/s11121-011-0210-0.
citation: Goebert D, Thompson D, Takeshita J, Beach C, Bryson P, Ephgrave K, Kent A, Kunkel M, Schechter J, Tate J. Depressive symptoms in medical students and residents: a multischool study. Acad Med. 2009 Feb;84(2):236-41. doi: 10.1097/ACM.0b013e31819391bb.
citation: Guille C, Zhao Z, Krystal J, Nichols B, Brady K, Sen S. Web-Based Cognitive Behavioral Therapy Intervention for the Prevention of Suicidal Ideation in Medical Interns: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Dec;72(12):1192-8. doi: 10.1001/jamapsychiatry.2015.1880.
citation: Rotenstein LS, Ramos MA, Torre M, Segal JB, Peluso MJ, Guille C, Sen S, Mata DA. Prevalence of Depression, Depressive Symptoms, and Suicidal Ideation Among Medical Students: A Systematic Review and Meta-Analysis. JAMA. 2016 Dec 6;316(21):2214-2236. doi: 10.1001/jama.2016.17324.
citation: Bentley KH, Boettcher H, Bullis JR, Carl JR, Conklin LR, Sauer-Zavala S, Pierre-Louis C, Farchione TJ, Barlow DH. Development of a Single-Session, Transdiagnostic Preventive Intervention for Young Adults at Risk for Emotional Disorders. Behav Modif. 2018 Sep;42(5):781-805. doi: 10.1177/0145445517734354. Epub 2017 Oct 13.
Clinical trial NCT01080911: 0.05 mg Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy
Official title: 0.05 vs. 0.1 Milligram Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy With/Without Anterior and Posterior Vaginoplasty
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Pain
Keywords: Spinal morphine
Vaginal hysterectomy
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2010-03-04
Enrollment: 72
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare the effect of spinal morphine between the dose 0.05 mg and 0.1 mg on the amount of morphine during the first 24 hours postoperative.


Eligibility criteria: Inclusion Criteria:

* Female ASA 1-3
* Undergoing vaginal hysterectomy with/without anterior and posterior vaginoplasty
* Can operate PCA device

Exclusion Criteria:

* History of allergy to the study drugs
* History of bleeding tendency
* History of infection at the back
* Patient refuse to have spinal anesthesia
* History of CAD or CVD

Primary outcomes:
measure: the amount of 24 hours morphine
timeFrame: 24 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Faculty of Medicine, Siriraj Hospital, mahidol University
Study officials:
affiliation: Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University
name: Sirilak Suksompong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00551811: Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone
Official title: A Dose Ranging Study to Assess the Effect of Pre-treatment With a Single Dose of Oral SB656933 on Lung Inflammation Following Challenge With Inhaled Ozone and Intermittent Exercise in Healthy Volunteers, Relative to Placebo
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: SB-656933-AAA,
ozone challenge
single dose,
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2007-10-31
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A study to evaluate the effect of SB-656933-AAA on the body after a single dose in subjects who have been challenged with ozone.


Eligibility criteria: Inclusion Criteria:

* Healthy subjects between 18-50 years.
* Females should be of non-child bearing potential.
* Non-smoking for at least 12 months.
* Normal lung function.
* Subjects should be able to produce acceptable sputum samples.

Exclusion Criteria:

* Any serious medical condition.
* Hepatitis B or C and/or HIV positive.
* Currently on regular medication except paracetamol.
* Body Mass Index \<20 or \>30.

Primary outcomes:
measure: To assess the effect of a single dose of SB-656933-AAA on ozone-induced inflammation in healthy subjects. Total number of neutrophils in sputum 6 hours after inhaling ozone.
timeFrame: 6 hours after inhaling ozone
Secondary outcomes:
measure: Total number of white cells in sputum 6 hours after inhaling ozone. Concentration of protein in sputum. Safety of SB-656933-AAA.
timeFrame: 6 hours after inhaling ozone
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011 Aug;72(2):282-93. doi: 10.1111/j.1365-2125.2011.03968.x.
Clinical trial NCT05675111: Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)
Official title: Endocrine-related Adverse Events Caused by Immune Checkpoint Inhibitors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Immune Checkpoint Inhibitor
Endocrine Toxicity
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
First posted: 2023-01-09
Enrollment: 12408
Sex: ALL
Minimum age (years): 18
Maximum age (years): 88
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 18 years or older, with cancers who received one dose or more of PD-1/PD-L1 inhibitors 5 academic centers from June 2018 to March 2021 were included.

Brief summary: Immune checkpoint inhibitor (ICI) includes agents that block cytotoxic T-cell-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1). Since the FDA-approval of the CTLA-4 inhibitor ipilimumab in 2011, ICI drugs have emerged as a powerful new tool in the treatment for several advanced cancers. Now indications for ICI have expanded dramatically due to their efficacy and include a wide array of cancer types. However, the administration of ICI, whereas, carry the risk of developing immune-related adverse events (irAEs) and may lead to serious and even fatal events. Endocrine dysfunctions are among the most common irAEs that have been reported in clinical trials with ICI, including thyroid dysfunction, hypopituitarism, primary adrenal insufficiency (PAI) and insulin-deficient diabetes (ICI-DM). However, it is difficult to acquire a complete picture of irAEs from randomized controlled trials (RCTs) due to limitations in the study design and realistic practicalities.


Eligibility criteria: Inclusion Criteria:

* Cancer patients who received one dose or more of PD-1/PD-L1 inhibitors

Exclusion Criteria:

* Insufficient reported details
* Patients younger than 18 years old
* in a double-blind study where treatment allocation cannot be resolved

Primary outcomes:
measure: irAEs
timeFrame: through study completion, an average of 2 year
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: First Affiliated Hospital, Nanjing Medical University
state: Jiangsu
Study officials:
affiliation: First Affiliated Hospital, Nanjing Medical University
name: Tao Yang, MD/PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01805011: Study on Normal Ranges of Lipids in Breast Milk of Healthy Mothers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Mothers
Lead sponsor: Société des Produits Nestlé (SPN)
Sponsor class: INDUSTRY
First posted: 2013-03-05
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy mothers

Brief summary: This trial is undertaken to better understand the ranges of functional components normally found in human milk. This will strengthen the scientific knowledge on breast-milk composition as a "gold standard".


Eligibility criteria: Inclusion Criteria:

* Gestational age between 37 and not above 42 weeks
* 18 years old ≤ Mother ≤ 40 years old
* 18.5 ≤ pre-pregnancy BMI ≤ 29
* Mothers willing to breastfeed for the first 4 months

Exclusion Criteria:

* Gestational diabetes
* HTA \< 140/90
* Mothers who are smokers while breast-feeding

Primary outcomes:
measure: levels of lipids
timeFrame: After 1 month of Breastfeeding
Secondary outcomes:
measure: profile and quantity of sugars
timeFrame: After 1 month of breastfeeding
Other outcomes:
Locations:
Study officials:
affiliation: NUHS
name: Le Ye Lee, Assistant Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sprenger N, Lee LY, De Castro CA, Steenhout P, Thakkar SK. Longitudinal change of selected human milk oligosaccharides and association to infants' growth, an observatory, single center, longitudinal cohort study. PLoS One. 2017 Feb 9;12(2):e0171814. doi: 10.1371/journal.pone.0171814. eCollection 2017.
Clinical trial NCT00512811: Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients
Official title: Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients: a Double-Blind Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Bronchiolitis
Keywords: furosemide
inhalation
dyspnea
spirometry
mustard gas
bronchiolitis
sulfur mustard
Lead sponsor: Baqiyatallah Medical Sciences University
Sponsor class: OTHER
First posted: 2007-08-08
Sex: MALE
Minimum age (years): 32
Maximum age (years): 83
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: to assess the efficacy of inhaled furosemide in mustard gas exposed patients with acute respiratory failure


Eligibility criteria: Inclusion Criteria:

* Patients with a history of exposure to sulfur mustard with a complaint of dyspnea

Exclusion Criteria:

* A contraindication for furosemide use;
* An accompanying disease in which other drugs effective for dyspnea were used

Primary outcomes:
measure: effect of furosemid inhalation on dyspnea
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: RCCI
Study officials:
affiliation: Research Center of Chemical Injuries, Baqiyatallah Medical Science University, Tehran, Iran
name: Mostafa Ghanei, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03911011: Physiological Values When Breathing in an Air-pocket. Mountain Lab 2019 (ML2019)
Official title: Gas Diffusion in and Out of an Air Pocket After a Simulated Snow Avalanche and Its Impacts on Human Physiological Parameters.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Accident Caused by Snow Avalanche
Keywords: avalanche, survival, physiology
Lead sponsor: Haukeland University Hospital
Sponsor class: OTHER
Collaborators: name: Ullevaal University Hospital
First posted: 2019-04-10
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: A field study designed as a crossover clinical trial.
Primary purpose: TREATMENT

Brief summary: The literature describes and report neurologic intact patients surviving an avalanche several hours after they were buried. The most important factor for surviving more than 15-35 min of burial is considered to be the presence of an air-filled space around the head and neck, termed an air pocket. Little is known how the inspired air is influenced by the patients breathing and how oxygen and carbon dioxide diffuse through snow.

Detailed description: In a controlled and simulated avalanche scenario the investigators want to investigate how oxygen (O2) and carbon dioxide (CO2) diffuse and how rebreathing of CO2 in addition to mild hypoxia influence standardized physiological parameters in two scenarios: Fresh air and no fresh air delivered into the air pocket. The project is a field study designed to measure and document gas diffusion through snow. The outcome measures are: (1) Concentration of O2 and CO2 in the air pocket and 50 cm from the pocket. (2) Time interval for development of threshold values for concentration of O2 and CO2. The investigators will also monitor physiologic measures such as: Electrocardiogram (ECG), continuous invasive blood pressure, cerebral oximetry, continuous pulse oximetry, transthoracic impedance, and gas content in expired air. Subjective evaluation of comfort will also be scored. Twenty healthy young volunteers with written consent to participate will be used as test subjects.

The study may have a clinical consequence for better outcome, for victims of avalanches by providing additional air or oxygen close to the patient. The study will also measure specific body measures and spirometry.

Eligibility criteria: Inclusion Criteria:

* Subject must be Healthy
* Subject must be non smoking
* Subject must have normal BMI

Exclusion Criteria:

* None

Primary outcomes:
measure: Time
timeFrame: 25 minutes
Secondary outcomes:
Other outcomes:
measure: Physiology
timeFrame: 25 minutes
Locations:
city: Bergen
country: Norway
facility: Haukeland University Hospital
Study officials:
affiliation: Director, Department for Anaesthesia and Intensive Care
name: Hanne Klausen, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03103711: Promotion of Emotional Well-being in Hospitalized Cancer Patients by Virtual Reality
Official title: A Brief Psychological Intervention Using Virtual Reality for the Promotion of Emotional Well-being in Hospitalized Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Keywords: Virtual reality
Well-being
Hospital
Lead sponsor: University of Valencia
Sponsor class: OTHER
Collaborators: name: Hospital Clínica Benidorm
name: Universitat Jaume I
name: Universitat Politècnica de València
First posted: 2017-04-06
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to analyze the effect of a brief psychological intervention supported by Information and Communication Technologies, on the subjective well-being of hospitalized cancer patients. Participants are randomly assigned to one of 2 conditions: Intervention condition (4 Virtual reality sessions) and Control condition (waiting list control group).


Eligibility criteria: Inclusion Criteria:

* adults with any cancer diagnosis
* hospitalized for at least 1 week
* Karnofsky functional state ≥50
* life expectancy ≥2 months

Exclusion Criteria:

* serious psychopathology
* cognitive impairment

Primary outcomes:
measure: The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983; adapted version of Tejero, Guimerá, Farré & Peri, 1986)
timeFrame: change from baseline at 1 week
measure: Fordyce Happiness Scale (Fordyce, 1988).
timeFrame: change from baseline at 1 week
Secondary outcomes:
measure: Visual Analog Scale: Mood.
timeFrame: 4 days along 1 week
measure: Visual Analog Scale: Emotional State. Change from pre to post session.
timeFrame: 4 days along 1 week
measure: Visual Analog Scale: Physical Discomfort. Change from pre to post session.
timeFrame: 4 days along 1 week
measure: Visual Analog Scale: Satisfaction with the Session Scale.
timeFrame: 4 days along 1 week
measure: Satisfaction with Intervention Scale (adapted version of Borkovec and Nau's, 1972)
timeFrame: 1 week
Other outcomes:
measure: The Brief Illness Perception Questionnaire (BIPQ) (Broadbent et al., 2006)
timeFrame: baseline
measure: Personal meaning of the illness (ad-hoc).
timeFrame: baseline
measure: Visual Analog Scale: Optimism
timeFrame: baseline
measure: Visual Analog Scale: Life satisfaction
timeFrame: baseline
Locations:
Study officials:
References:
Clinical trial NCT04752111: Dose Esmolol Infusion Have an Adjuvant Effect to TAP Block for Pain Control in Laparoscopic Cholecystectomy.
Official title: Dose Esmolol Infusion Have an Adjuvant Effect to Transversus Abdominis Plane Block for Pain Control in Laparoscopic Cholecystectomy: A Randomized Controlled Double-blind Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postoperative Pain
Keywords: Esmolol infusion
TAP block
cholecystectomy
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2021-02-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pain after laparoscopy differs considerably from that seen after laparotomy. Laparotomy results mainly in parietal pain (abdominal wall), where as Pain in laparoscopy results from stretching of the intra-abdominal cavity, peritoneal inflammation, and diaphragmatic irritation caused by residual carbon-dioxide in the peritoneal cavity. The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). While esmolol is an ultra-short acting intravenous β-blocker having a rapid onset and offset effect. It provides an unprecedented level of tolerability and safety in the perioperative setting. When used as an adjunct, it has been shown to improve the postoperative recovery by reducing postoperative pain intensity and intraoperative anesthetic and opioid requirements and preventing opioid-induced hyperalgesia . The mechanism of this synergistic effect is uncertain, but both pharmacokinetic and pharmacodynamics interactions with anesthetic drugs have been proposed.


Eligibility criteria: Inclusion Criteria:

1. ASA grade I/II patients undergoing laparoscopic cholecystectomy .
2. Age group of 18 -60 years.
3. Patients giving valid informed consent.

Exclusion Criteria:

1. Patient refusal
2. Patients belonging to ASA grade III and grade IV .
3. Coagulation disorders.
4. Patients with known allergy to one of the used drugs.
5. Extreme obesity (BMI \>35)
6. Patients with cardiac, pulmonary, hepatic or renal disorders
7. Pregnancy
8. Drug abusers

Primary outcomes:
measure: pain rescue-analgesia consumption
timeFrame: 24 hours postoperative
Secondary outcomes:
measure: Visual analogue pain score
timeFrame: every 0,2,4,6,12, up to 24 hours postoperative
measure: Intraoperative hemodynamic data
timeFrame: 30 minutes after induction of anesthesia
measure: Postoperative nausea and vomiting
timeFrame: 24 hours postoperative
measure: Patient satisfaction
timeFrame: 24 hours postoperative
Other outcomes:
Locations:
city: Benha
country: Egypt
facility: Samar Rafik Mohamed Amin
state: Qalubia
Study officials:
References:
Clinical trial NCT04484311: Non-curative ESDs: Assessing the Rates and Risk Factors for Residual Neoplasia
Official title: Multi-center Survey on Non-curative ESDs: Assessing the Rates and Risk Factors for Residual Neoplasia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gastric Neoplasm
Esophageal Neoplasms
Colorectal Neoplasms
Keywords: Endoscopic therapy
Endoscopic submucosal dissection
Lead sponsor: Universidade do Porto
Sponsor class: OTHER
First posted: 2020-07-23
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients submitted to ESD due to neoplastic lesions of the gastrointestinal tract.

Brief summary: Short and long outcomes of ESD are well described, particularly in Eastern series. However, the outcome of non-curative ESDs is scarcely reported in the west (particularly among non-gastric or submucosal lesions). Therefore, the aim of this project is to describe the European experience with non-curative ESDs, analysing all the consecutive ESDs performed in several reference centers, assessing the presence of residual lesion in the endoscopic follow-up or in the surgical specimen.


Eligibility criteria: Inclusion Criteria:

* All patients submitted to ESD due to neoplastic lesions of the gastrointestinal tract

Exclusion Criteria:

* Patients without endoscopic follow-up or surgery will be excluded from the analysis

Primary outcomes:
measure: Residual neoplasia
timeFrame: 2010-2020
Secondary outcomes:
Other outcomes:
Locations:
city: Porto
country: Portugal
facility: Hospital S. João
Study officials:
affiliation: Gastrointestinal Department, Centro Hospitalar S. João, Porto, Portugal
name: João Santos-Antunes
role: PRINCIPAL_INVESTIGATOR
affiliation: Gastrointestinal Department, Centro Hospitalar S. João, Porto, Portugal
name: Guilherme Macedo, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Santos-Antunes J, Pioche M, Ramos-Zabala F, Cecinato P, Gallego Rojo FJ, Barreiro P, Felix C, Sferrazza S, Berr F, Wagner A, Lemmers A, Figueiredo Ferreira M, Albeniz E, Uchima H, Kuttner-Magalhaes R, Fernandes C, Morais R, Gupta S, Martinho-Dias D, Rios E, Faria-Ramos I, Marques M, Bourke MJ, Macedo G. Risk of residual neoplasia after a noncurative colorectal endoscopic submucosal dissection for malignant lesions: a multinational study. Endoscopy. 2023 Mar;55(3):235-244. doi: 10.1055/a-1906-8000. Epub 2022 Jul 21.